Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

Pennsylvania officials continue to retool the state’s vaccination plan to fall in line with recommendations from federal groups and further define who can get the vaccine and when, releasing the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio DENVER — A phase 3 trial of ...

HONG KONG--(BUSINESS WIRE)--Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising ...

The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, ...

NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA ...

As businesses adapt in the wake of the pandemic, they may face legal action by customers or employees related to COVID-19. However, “essential” businesses as well as health care services can limit ...

As we previously reported, New York’s plan to reopen, “New York Forward” (“NYF” or “Plan”), authorizes a gradual reopening of nonessential businesses. On May 29, 2020, the state initiated Phase Two of ...

Results from safety analyses were generally consistent with the well-established safety profile of onabotulinumtoxinA. 1 NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today ...